Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles
Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.5% after EyePoint Pharmaceuticals (NASDAQ:EYPT) said its DURAVYU missed the primary endpoint in a Phase 3 wet AMD LUGANO trial versus aflibercept. EyePoint cited an asymmetric 9/211 patient subgroup with vision loss unrelated to wet AMD; excluding it, DURAVYU was non-inferior. EyePoint plans an FDA NDA in 1H 2027.
How this was made
The 30-second read
Why it matters
EyePoint’s Phase 3 primary endpoint miss is a direct competitive read-across for the wet AMD hydrogel space, explaining the immediate relative repricing between EYPT and OCUL.
Market read
A wet AMD Phase 3 primary endpoint miss is a high-salience catalyst for the retinal pipeline competitive set, driving same-day relative moves.
What to watch
The article does not provide DURAVYU safety outcomes or how regulators may view the asymmetric cohort; OCUL’s move may fade without its own upcoming trial milestones.
Background
Ocular Therapeutix and EyePoint are both developing extended-release, bioerodible hydrogel treatments for retinal diseases, including wet AMD.
Ticker impact
Ocular Therapeutix shares rose 7.5% after competitor EyePoint’s DURAVYU missed the primary endpoint in a pivotal Phase 3 wet AMD trial.
Likely near-term bid on relative-competition optics, with follow-through dependent on OCUL’s own clinical readouts.
The article ties OCUL’s same-day move to EyePoint’s Phase 3 primary endpoint miss, a direct read-across catalyst for the wet AMD competitive set.
EyePoint’s DURAVYU missed the primary endpoint in the LUGANO Phase 3 wet AMD trial, with an ad hoc analysis excluding a vision-loss cohort.
Downward pressure likely, though the stock may stabilize if investors focus on secondary endpoints and planned FDA filing.
The text states the primary endpoint was not achieved in the full dataset, which is typically the key driver for Phase 3 success, even with secondary positives.
Market effects
Wet AMD extended-release hydrogel competition gets a negative signal from EyePoint’s primary endpoint miss, potentially repricing peer expectations.
Primarily US-listed biotech sentiment; limited direct regional spillover beyond retinal disease peers.
Wet AMD trial outcomes can influence global investor perception of late-stage ophthalmology pipelines, but impact is mostly within the US peer group.
Counterpoint
Secondary endpoints and the ad hoc non-inferiority result may limit downside, especially if the excluded cohort is viewed as a statistical anomaly rather than a safety/efficacy flaw.
Key entities
- companyOcular Therapeutix Inc
OCUL shares rose 7.5% after EyePoint’s DURAVYU wet AMD Phase 3 primary endpoint miss.
- companyEyePoint Pharmaceuticals
EYPT reported DURAVYU missed the primary endpoint in the LUGANO Phase 3 wet AMD trial, with secondary endpoints showing reduced treatment burden.
- productDURAVYU
EyePoint’s extended-release treatment evaluated in the LUGANO Phase 3 wet AMD trial.
- clinical_trialLUGANO trial
Pivotal Phase 3 wet AMD study where DURAVYU failed the primary endpoint in the full dataset.
- clinical_trialLUCIA trial
Another EyePoint Phase 3 program with topline data expected in Q4 2026, informing a planned NDA filing in H1 2027.
